ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma by Carvalho, D, Taylor, KR, Olaciregui, NG, Molinari, V, Clarke, M, Mackay, A, Ruddle, R, Henley, A, Valenti, M, Hayes, A, Brandon, ADH, Eccles, SA, Raynaud, F, Boudhar, A, Monje, M, Popov, S, Moore, AS, Mora, J, Cruz, O, Vinci, M, Brennan, PE, Bullock, AN, Carcaboso, AM, Jones, C

Design, synthesis and characterization of covalent KDM5 inhibitors by Vazquez-Rodriguez, S, Wright, M, Rogers, C, Cribbs, A, Velupillai, S, Philpott, M, Lee, H, Dunford, J, Huber, K, Robers, M, Vasta, J, Thezenas, M, Bonham, S, Kessler, B, Bennett, J, Fedorov, O, Raynaud, F, Donovan, A, Blagg, J, Bavetsias, V, Oppermann, U, Bountra, C, Kawamura, A, Brennan, P

Assessing histone demethylase inhibitors in cells: lessons learned by Hatch, S, Yapp, C, Montenegro, R, Savitsky, P, Gamble, V, Tumber, A, Ruda, G, Bavetsias, V, Fedorov, O, Atrash, B, Raynaud, F, Lanigan, R, Carmichael, L, Tomlin, K, Burke, R, Westway, S, Brown, J, Prinjha, R, Martinez, E, Oppermann, U, Schofield, C, Bountra, C, Kawamura, A, Blagg, J, Brennan, P, Rossanese, O, Müller, S

8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors by Bavetsias, V, Lanigan, R, Ruda, G, Atrash, B, McLaughlin, M, Tumber, A, Mok, N, Le Bihan, Y, Dempster, S, Boxall, K, Jeganathan, F, Hatch, S, Savitsky, P, Velupillai, S, Krojer, T, England, K, Sejberg, J, Thai, C, Donovan, A, Pal, A, Scozzafava, G, Bennett, J, Kawamura, A, Johansson, C, Szykowska, A, Gileadi, C, Burgess-Brown, N, von Delft, F, Oppermann, U, Walters, Z, Shipley, J, Raynaud, F, Westaway, S, Prinjha, R, Fedorov, O, Burke, R, Schofield, C, Westwood, I, Bountra, C, Müller, S, van Montfort, R, Brennan, P, Blagg, J